“We continue to operate with financial discipline, focusing our resources on advancing our cell therapy programs toward the clinical stage,” said Sanjeev Luther, President and CEO of Ernexa Therapeutics (ERNA). “This approach gives us the flexibility to pursue strategic collaborations and progress our lead programs, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease. We are well-positioned to advance our clinical and regulatory strategies toward our first-in-human study next year.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- 3 Penny Stocks to Watch Now, 10/30/25
- Ernexa Therapeutics, Cellipont Bioservices enter collaboration